AI-powered discovery platform EVA™ drives development of a highly selective T-cell engager showing over 90% tumor growth inhibition in pre-clinical studies.
London, 13 November 2025...
Neurocrine Biosciences, Inc. has officially published top-line data from a Phase 4 study named KINECT-PRO™ data, which showcases clinically meaningful and sustained effects of...
Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, has officially published results from...
During the earliest stages of clinical drug development, pharmaceutical and biotech companies need to make critical go / no-go decisions for their investigational products....